Orbimed Advisors LLC cut its holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 21.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,438,182 shares of the company’s stock after selling 393,465 shares during the quarter. Orbimed Advisors LLC owned about 3.92% of Aerie Pharmaceuticals worth $69,896,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of AERI. Vanguard Group Inc. increased its stake in Aerie Pharmaceuticals by 55.0% in the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock valued at $113,446,000 after purchasing an additional 766,300 shares during the period. Senzar Asset Management LLC acquired a new position in Aerie Pharmaceuticals in the second quarter valued at $20,568,000. Broadfin Capital LLC acquired a new position in Aerie Pharmaceuticals in the second quarter valued at $16,291,000. AXA acquired a new position in Aerie Pharmaceuticals in the second quarter valued at $10,961,000. Finally, Russell Investments Group Ltd. increased its stake in Aerie Pharmaceuticals by 813.5% in the second quarter. Russell Investments Group Ltd. now owns 232,610 shares of the company’s stock valued at $12,223,000 after purchasing an additional 207,146 shares during the period.
Aerie Pharmaceuticals Inc (NASDAQ AERI) opened at $60.05 on Friday. Aerie Pharmaceuticals Inc has a one year low of $35.50 and a one year high of $66.60. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78.
A number of brokerages have recently issued reports on AERI. Mizuho reiterated a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 25th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Needham & Company LLC reiterated a “buy” rating and set a $65.00 price target on shares of Aerie Pharmaceuticals in a research note on Sunday, September 17th. Cantor Fitzgerald set a $69.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 16th. Finally, Canaccord Genuity set a $65.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $71.43.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/10/orbimed-advisors-llc-sells-393465-shares-of-aerie-pharmaceuticals-inc-aeri.html.
Aerie Pharmaceuticals Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).
Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.